Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 05 - 20 tags : Risk save search
ASCO 2021 Preview: Making Breast Cancer Risk Assessment More Inclusive
Published: 2021-05-20 (Crawled : 00:00) - myriad.com
MYGN | $18.595 0.57% 0.56% 510K
|
Health Technology
|
| O: 1.54%
H: 0.65%
C: -0.86%
risk cancer breast cancer
Chubb Launches "Global Risk Spotlights" Advisory Series for U.S. Multinational Clients and Brokers
Published: 2021-05-20 (Crawled : 19:00) - prnewswire.com
CB | News | $249.88 -0.64% -0.85% 1.5M
|
Finance
|
| O: 0.28%
H: 1.3%
C: 0.05%
risk
Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors
Published: 2021-05-20 (Crawled : 12:00) - biospace.com/
CSTL | $20.06 2.3% 2.05% 200K
|
Health Technology
|
| O: 0.56%
H: 3.2%
C: -1.13%
risk results cell carcinoma
Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial
Published: 2021-05-20 (Crawled : 11:00) - biospace.com/
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.33%
H: 1.99%
C: 1.2%
diabetes risk cardiovascular insulin cardio trial glargine tirzepatide
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.